Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification

Abstract

BackgroundPrimary pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare type of non-small cell lung cancer (NSCLC). Currently, anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) has become an important treatment for NSCLC. Anti-human PD-1 monoclonal antibodies, such as nivolumab, significantly prolong the survival time of patients with advanced lung adenocarcinoma and lung squamous cell carcinoma. However, there are few reports on the therapeutic effect, drug resistance mechanism, and strategies to overcome resistance to anti-PD-1/PD-L1 treatment in advanced pulmonary LELC. We report the case of a patient with advanced pulmonary LELC harboring fibroblast growth factor receptor (FGFR)3 gene amplification that showed resistance to nivolumab. After treatment with anlotinib, a multi-targeted small-molecule tyrosine kinase inhibitor, the patient’s resistance to nivolumab was reversed. She achieved long-term disease remission with a combination of anlotinib and nivolumab treatment.Case PresentationA 68-year-old woman was diagnosed with stage IVA pulmonary LELC. After multiple-line chemotherapy, her disease progressed. Since the PD-L1 expression rate of the patient was 90%, nivolumab was administered. However, the therapeutic effect of nivolumab was not ideal; the disease continued to progress, and a new cervical lymph node metastasis appeared. FGFR3 gene amplification was detected in lymph node metastasis. Based on this gene abnormality, we added anlotinib to the treatment. After two cycles of anlotinib and nivolumab, the metastatic focus of the patient was significantly reduced. The patient continued to receive this combined treatment and achieved remission for more than 15 months.ConclusionPulmonary LELC with FGFR3 gene amplification may not respond well to nivolumab monotherapy. The combination of anlotinib and nivolumab can reverse the resistance to nivolumab in pulmonary LELC with FGFR3 gene amplification.

Immunotherapy and Antivascular Targeted Therapy in Patients’ Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge

“…Antivascular targeted therapy is currently one of the important modalities in the treatment of malignant tumors and has shown good therapeutic effects on lung and intestinal cancers. Available data suggest that there is a synergistic effect of antivascular targeted therapy and immunotherapy [ 52 – 55 ], and some studies suggest that antivascular targeted therapy can reverse PD-1 resistance to some extent [ 56 ]. Retrospective data analysis suggests that antivascular targeted therapy has also shown good disease control rates in patients with specific tumors after organ transplantation.…”

A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol

“…Xu's published work in World Journal of Surgical Oncology presented a case of lung adenocarcinoma with HER2 p. Asp769Tyr mutation that was successfully treated with a combination of afatinib and anlotinib. 163,[180][181][182] Lorlatinib is a targeted therapy drug employed for the treatment of non-small cell lung cancer (NSCLC), acting as a small molecule tyrosine kinase inhibitor. Lorlatinib functions by suppressing the activity of anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and proto-oncogene tyrosine-protein kinase (RET).…”

Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study

“…Preclinical researches and case reports demonstrated that anlotinib may modulate the tumor microenvironment and act synergistically with immune checkpoint inhibitors. [11][12][13][14][15][16][17] Current studies have shown encouraging efficacy of the clinical use of anlotinib combination therapy, and a case reported first-line pemetrexed and carboplatin plus anlotinib achieved CR. [18][19][20][21][22] However, the sample size of current studies is small and more studies are still needed to confirm the efficacy and safety of anlotinib combination therapy in different patients with NSCLC.…”